Skip to Content

Tivicay Approval History

  • FDA approved: Yes (First approved August 12th, 2013)
  • Brand name: Tivicay
  • Generic name: dolutegravir
  • Dosage form: Tablets
  • Company: ViiV Healthcare
  • Treatment for: HIV Infection

Tivicay (dolutegravir) is an integrase inhibitor indicated for use in combination with other antiretroviral (ARV) agents for the treatment of HIV-1.

Development History and FDA Approval Process for Tivicay

Aug 12, 2013Approval FDA Approves Tivicay (dolutegravir) to Treat HIV Infection
Dec 18, 2012ViiV Healthcare Announces Regulatory Submissions for Dolutegravir in the EU, US and Canada

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.